Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference
30 Janeiro 2025 - 9:00AM
Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a
biopharmaceutical company focused on developing modality-agnostic
targeted therapies, today announced that Nadim Ahmed, Chief
Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical
Officer, will participate in a fireside chat at the Guggenheim
Securities SMID Cap Biotech Conference, being held in New York on
February 5 and 6, 2025.
The fireside chat is scheduled for Wednesday, February 5, 2025,
at 9:30 a.m. ET. A webcast of the fireside chat will be available
under the Events and Presentations section of the Company’s
investor relations website
at https://cullinantherapeutics.com/events-and-presentations/.
About Cullinan TherapeuticsCullinan
Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company
dedicated to creating new standards of care for patients. Cullinan
has strategically built a diversified portfolio of clinical-stage
assets that inhibit key drivers of disease or harness the immune
system to eliminate diseased cells in both autoimmune diseases and
cancer. Cullinan’s portfolio encompasses a wide range of
modalities, each with the potential to be best and/or first in
class. Anchored in a deep understanding of oncology, immunology,
and translational medicine, we create differentiated ideas,
identify the most appropriate targets, and select the optimal
modality to develop transformative therapeutics across a wide
variety of autoimmune and cancer indications. We push conventional
boundaries from candidate selection to differentiated therapeutic,
applying rigorous go/no go criteria at each stage of development to
fast-track only the most promising molecules to the clinic and,
ultimately, commercialization. With deep scientific expertise, our
teams exercise creativity and urgency to deliver on our promise to
bring new therapeutic solutions to patients. Learn more about
Cullinan at https://cullinantherapeutics.com/, and follow us
on LinkedIn and X.
Contacts:
Investor RelationsNick Smith+1
401.241.3516nsmith@cullinantx.com
MediaRose Weldon+1
215.801.7644rweldon@cullinantx.com
Cullinan Therapeutics (NASDAQ:CGEM)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025
Cullinan Therapeutics (NASDAQ:CGEM)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025